MBX Biosciences, Inc.

CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its initial public offering of 10,200,000 shares of its common stock at […] The post MBX Biosciences Announces Pricing of Initial Public Offering appeared first on MBX Biosciences.

CARMEL, Ind., September 9, 2024 (GLOBE NEWSWIRE) – MBX Biosciences, Inc. (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the launch of its initial public offering of 8,500,000 shares of its common stock pursuant to a […] The post MBX Biosciences Announces Launch of Initial Public Offering appeared first on MBX Biosciences.

Topline results expected in Q3 2025  CARMEL, Ind., August 12, 2024 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it has dosed the first patient in its Phase 2 Avail™ trial of […] The post MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism  appeared first on MBX Biosciences.

Financing led by Deep Track Capital, with new investments from Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc. Proceeds to support ongoing Phase 2 clinical study of once-weekly MBX-2109 in hypoparathyroidism and acceleration of early-stage pipeline programs CARMEL, Ind., August 5, 2024 — MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused […] The post MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform appeared first on MBX Biosciences.

CARMEL, Ind., June 25, 2024 — MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Salomon (Sam) Azoulay, M.D, as Chief Medical Officer (CMO). Dr. Azoulay is an accomplished physician-scientist with over 35 years of […] The post MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer appeared first on MBX Biosciences.

CARMEL, Ind., February 5, 2024 — MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Steven Ryder, M.D, Chief Medical Officer of Rallybio, to its Board of Directors. Dr. Ryder is an accomplished biopharmaceutical executive with over 35 years […] The post MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors appeared first on MBX Biosciences.

CARMEL, Ind., January 31, 2024 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th, 2024, at […] The post MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference appeared first on MBX Biosciences.

CARMEL, Ind., December 20, 2023 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024, at 11:30 a.m. […] The post MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference appeared first on MBX Biosciences.

CARMEL, Ind., November 1, 2023 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Michelle Graham as Chief Human Resources Officer. Ms. Graham is a seasoned global executive with 25+ years of experience leading human resources across […] The post MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer appeared first on MBX Biosciences.

CARMEL, Ind., October 31, 2023 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference on Tuesday, November 14th, 2023, at 2:25 p.m. Eastern Time […] The post MBX Biosciences to Participate in Stifel 2023 Healthcare Conference appeared first on MBX Biosciences.